Table 4 Additional efficacy and safety data compared between the groups
Adalimumab (ADA) (n=111) | Infliximab (IFX) (n=282) | P value | |
|---|---|---|---|
Time of treatment with anti-TNF (months) | 28.93 ±23.36 | 41.23 ±33.14 | <0.001 |
Secondary loss of response | 44 (44.00) | 96 (36.92) | <0.001 |
Anti-TNF dose optimization | 42 (40.78) | 101 (38.55) | <0.001 |
Switch of biological therapy | 37 (35.58) | 61 (23.28) | 0.015 |
Colectomy | 5 (4.50) | 18 (6.59) | 0.007 |
Overall adverse events | 13 (11.71) | 44 (16.67) | 0.3902 |
Infectious | 7 (6.93) | 25 (9.51) | 0.4373 |
Infusion or injection reactions | 3 (2.97) | 6 (2.42) | 0.7218 |
Other adverse events | 9 (9.0) | 25 (9.54) | 0.8744 |
Death | 1 (1.02) | 3 (1.17) | 0.317 |